136 research outputs found
50th Anniversary of âAmeslan Prohibitedâ: Celebrating Betty G. Millerâs Creativity
The art piece known as âAmeslan Prohibitedâ may currently enjoy an excellent standing in the eyes of deaf people in the United States and abroad, but this was not the case in 1972 when it was first exhibited to the public. Fifty years have passed with the art piece shifting from being thought of as outrageous by many viewers to being highly acclaimed. âAmeslan Prohibitedâ refers to societyâs historical and contemporary lack of support for the language of deaf people in the United States, American Sign Language (ASL). The now deceased Betty Gloria Miller was the creator of âAmeslan Prohibitedâ; she lived her life as a deaf woman and was a strong advocate for ASL and social justice. In this paper, Miller as an artist is subject to theoretical discussion based on Mihaly Csikszentmihalyiâs (1997) systems model of creativity. This along with an interview conducted with Millerâs life partner, Nancy Creighton produces some new and in-depth insights on Deaf art. The author of this paper closes with her thoughts and insights as a deaf signer and a viewer of âAmeslan Prohibited.
The Carnegie Supernova Project: First Near-Infrared Hubble Diagram to z~0.7
The Carnegie Supernova Project (CSP) is designed to measure the luminosity
distance for Type Ia supernovae (SNe Ia) as a function of redshift, and to set
observational constraints on the dark energy contribution to the total energy
content of the Universe. The CSP differs from other projects to date in its
goal of providing an I-band {rest-frame} Hubble diagram. Here we present the
first results from near-infrared (NIR) observations obtained using the Magellan
Baade telescope for SNe Ia with 0.1 < z < 0.7. We combine these results with
those from the low-redshift CSP at z <0.1 (Folatelli et al. 2009). We present
light curves and an I-band Hubble diagram for this first sample of 35 SNe Ia
and we compare these data to 21 new SNe Ia at low redshift. These data support
the conclusion that the expansion of the Universe is accelerating. When
combined with independent results from baryon acoustic oscillations (Eisenstein
et al. 2005), these data yield Omega_m = 0.27 +/- 0.0 (statistical), and
Omega_DE = 0.76 +/- 0.13 (statistical) +/- 0.09 (systematic), for the matter
and dark energy densities, respectively. If we parameterize the data in terms
of an equation of state, w, assume a flat geometry, and combine with baryon
acoustic oscillations, we find that w = -1.05 +/- 0.13 (statistical) +/- 0.09
(systematic). The largest source of systematic uncertainty on w arises from
uncertainties in the photometric calibration, signaling the importance of
securing more accurate photometric calibrations for future supernova cosmology
programs. Finally, we conclude that either the dust affecting the luminosities
of SNe Ia has a different extinction law (R_V = 1.8) than that in the Milky Way
(where R_V = 3.1), or that there is an additional intrinsic color term with
luminosity for SNe Ia independent of the decline rate.Comment: 44 pages, 23 figures, 9 tables; Accepted for publication in the
Astrophysical Journa
P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries
The critical role for ADP in arterial thrombogenesis was established by the clinical success of P2Y12 antagonists, currently used at doses that block 40â50% of the P2Y12 on platelets. This study was designed to determine the role of P2Y12 in platelet thrombosis and how its complete absence affects the thrombotic process. P2Y12-null mice were generated by a gene-targeting strategy. Using an in vivo mesenteric artery injury model and real-time continuous analysis of the thrombotic process, we observed that the time for appearance of first thrombus was delayed and that only small, unstable thrombi formed in P2Y12â/â mice without reaching occlusive size, in the absence of aspirin. Platelet adhesion to vWF was impaired in P2Y12â/â platelets. While adhesion to fibrinogen and collagen appeared normal, the platelets in thrombi from P2Y12â/â mice on collagen were less dense and less activated than their WT counterparts. P2Y12â/â platelet activation was also reduced in response to ADP or a PAR-4âactivating peptide. Thus, P2Y12 is involved in several key steps of thrombosis: platelet adhesion/activation, thrombus growth, and stability. The data suggest that more aggressive strategies of P2Y12 antagonism will be antithrombotic without the requirement of aspirin cotherapy and may provide benefits even to the aspirin-nonresponder population
CalDAG-GEFI Deficiency Reduces Atherosclerotic Lesion Development in MiceSignificance
Platelets are important to the development and progression of atherosclerotic lesions. However, relatively little is known about the contribution of platelet signaling to this pathological process. Our recent work identified two independent, yet synergistic signaling pathways that lead to the activation of the small GTPase Rap1; one mediated by the guanine nucleotide exchange factor, CalDAG-GEFI (CDGI), the other by P2Y12, a platelet receptor for ADP and the target of anti-platelet drugs. In this study, we evaluated lesion formation in atherosclerosis-prone low-density lipoprotein receptor deficient (Ldlrâ/â) mice lacking CDGI and/or P2Y12 in hematopoietic cells
The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling
The adenosine diphosphate (ADP) receptor P2RY12 (purinergic receptor P2Y, G protein coupled, 12) plays a critical role in platelet aggregation, and P2RY12 inhibitors are used clinically to prevent cardiac and cerebral thrombotic events. Extracellular ADP has also been shown to increase osteoclast (OC) activity, but the role of P2RY12 in OC biology is unknown. Here, we examined the role of mouse P2RY12 in OC function. Mice lacking P2ry12 had decreased OC activity and were partially protected from age-associated bone loss. P2ry12(â/â) OCs exhibited intact differentiation markers, but diminished resorptive function. Extracellular ADP enhanced OC adhesion and resorptive activity of WT, but not P2ry12(â/â), OCs. In platelets, ADP stimulation of P2RY12 resulted in GTPase Ras-related protein (RAP1) activation and subsequent α(IIb)ÎČ(3) integrin activation. Likewise, we found that ADP stimulation induced RAP1 activation in WT and integrin ÎČ(3) gene knockout (Itgb3(â/â)) OCs, but its effects were substantially blunted in P2ry12(â/â) OCs. In vivo, P2ry12(â/â) mice were partially protected from pathologic bone loss associated with serum transfer arthritis, tumor growth in bone, and ovariectomy-induced osteoporosis: all conditions associated with increased extracellular ADP. Finally, mice treated with the clinical inhibitor of P2RY12, clopidogrel, were protected from pathologic osteolysis. These results demonstrate that P2RY12 is the primary ADP receptor in OCs and suggest that P2RY12 inhibition is a potential therapeutic target for pathologic bone loss
Precision health: A nursing perspective
Precision health refers to personalized healthcare based on a person's unique genetic, genomic, or omic composition within the context of lifestyle, social, economic, cultural and environmental influences to help individuals achieve well-being and optimal health. Precision health utilizes big data sets that combine omics (i.e. genomic sequence, protein, metabolite, and microbiome information) with clinical information and health outcomes to optimize disease diagnosis, treatment and prevention specific to each patient. Successful implementation of precision health requires interprofessional collaboration, community outreach efforts, and coordination of care, a mission that nurses are well-positioned to lead. Despite the surge of interest and attention to precision health, most nurses are not well-versed in precision health or its implications for the nursing profession. Based on a critical analysis of literature and expert opinions, this paper provides an overview of precision health and the importance of engaging the nursing profession for its implementation. Other topics reviewed in this paper include big data and omics, information science, integration of family health history in precision health, and nursing omics research in symptom science. The paper concludes with recommendations for nurse leaders in research, education, clinical practice, nursing administration and policy settings for which to develop strategic plans to implement precision health
- âŠ